ANTERO-4: VIPUN Gastric Monitoring System in an Erythromycin Model — ANTERO-4  

Gastric Motility Clinical Trial

Official title: ANTERO-4: A Clinical Investigation of the Effects of Erythromycin on Gastric Motility, Assessed With the VIPUN Gastric Monitoring System in Healthy Adults

Status Terminated

Clinical Trial Summary

It has been demonstrated that the VIPUN Gastric Monitoring System (GMS) can discriminate healthy physiological and pharmacologically-inhibited gastric motility, using a codeine-model in healthy adults (S60320 / AFMPS80M0687).

Erythromycin is a gastroprokinetic agent, known to stimulate gastric contractility. A single dose of 200 mg erythromycin has been shown to induce a prolonged period of enhanced phasic contractile activity.

The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults.

The performance of the VIPUN GMS can be enhanced by data-driven optimization of the VIPUN Motility Algorithm, used to quantify gastric motility.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Gastric Motility

• NCT number: NCT04066231
• Study type: Interventional
• Source: Universitaire Ziekenhuizen Leuven
• Status: Terminated
• Phase: N/A
• Start date: September 7, 2019
• Completion date: March 10, 2020